BOULDER, Colo.--(BUSINESS WIRE)--Array BioPharma Inc. (NASDAQ: ARRY) today announced that Ron Squarer has been appointed Chief Executive Officer, effective immediately. Mr. Squarer has also been named to the Array Board of Directors.  

Colorado BioScience Association Seeks Region’s Top Start-up Companies for Venture Showcase Competition at BioWest 2012 

DENVER--(BUSINESS WIRE)--Accelr8 Technology Corporation (Amex: AXK) announced today that an investment group formed by Jack Schuler, John Patience, and Larry Mehren will invest a total of up to $35 million in Accelr8’s common stock. The purpose is to complete the product development and market introduction of Accelr8’s BACcel™ culture-free, diagnostic system for same-shift identification and antibiotic resistance testing of bacterial and fungal pathogens.  

Awarding $216,282 to Colorado researchers in 2012. Including this year's awards, C2D2 has provided more than $660,000 to 11 drug discovery programs from all major research institutions in Colorado.  

2012 WEEKLY GENERAL LEGISLATIVE REPORT 4-20 

LEADING DEVELOPER OF MOLECULAR-BASED TESTS FOR ONCOLOGY NAMES
BURNS MARKETING AS ITS AGENCY OF RECORD 

Bennet Measures Aim to Improve Drug Safety, Bring Breakthrough Treatments to Patients More Quickly, Advance Medical Device Innovation and Avoid Critical Drug Shortages 

By Beth Potter